Abstracts zu den Beiträgen auf dem ASCO 2022
KEYNOTE 799
Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC. | Journal of Clinical Oncology (ascopubs.org)
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8508
NADIM II
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial) | Journal of Clinical Oncology (ascopubs.org)
https://ascopubs.org/doi/full/10.1200/JCO.21.02660
CHECKMATE 816
Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816. | Journal of Clinical Oncology (ascopubs.org)
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA8511
